MARKET WIREYahoo Finance • 1d ago
How to Play TRXB Stock After the TRex Bio IPOYahoo Finance report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
Why TRXB Stock slipped -0.73% Today — RQD Quant Desk Flash
$13.64 -0.73% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $13.60
TRex Bio Inc. (TRXB) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $377.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TRXB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TRXB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, TRex Bio Inc. (NASDAQ: TRXB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $13.64 (-0.73% 1D, market cap $377.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TRXB ranks #288 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TRXB compare to AGMB and TECX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TRXB carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AGMB (AgomAb Therapeutics NV) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $368.9M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, TRXB leads on earnings multiple (N/A) while TECX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TRXB?
▼
For TRex Bio Inc. (TRXB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #288 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $13.60 (-0.32%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRXB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY TRXB SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)
SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($10.6M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$13.60+6.2% Next Q
40
Q2 (-2Q)Grade D$14.44-4.5% Next Q
43
Q3 (-1Q)Grade D$13.79-1.1% Next Q
45
CurrentGrade D$13.64-5.6% Hist 90D α
48
Trajectory: D (40) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TRXB Turnaround Squeeze
While TRXB currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.18) and Max Pain ($14.32) forces dealer call-delta covering toward $17.39.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRXB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TRXB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TRXB Stock slipped -0.73% Today — RQD Quant Desk Flash
TRex Bio Inc. (TRXB) slipped -0.73% to $13.64, trading at 16% of its 52-week range ($13.1 – $16.56). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($13.1 – $16.56) with RSI-14 at 49.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $13.64 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $10.6M annual free cash flow.
Live TRXB Headlines & Catalysts
MARKET WIREFierce Biotech • 1d ago
TRex rakes in $117M IPO, while Retension reveals $45M listingFierce Biotech report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Eli Lilly-backed TRex Bio targets up to $133M in U.S. IPOSeeking Alpha report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBarron's • 1d ago
TRex Bio Inc. Stock Grades | TRXBBarron's report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
TRex Bio, Inc. Income Statement – NASDAQ:TRXBTradingView report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 1d ago
TRex Bio, Inc. (TRXB) stock price, news, quote and historyYahoo Finance UK report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
TRex Bio (TRXB) Stock Price, News & AnalysisStock Titan report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRERenaissance Capital • 1d ago
TRXB IPO News - Autoimmune and inflammatory diseases biotech TRex Bio sets terms for $125 million IPORenaissance Capital report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeekingAlpha • 3d ago
Apple Leads Packed Earnings Calendar As Investors Eye Tech, Pharma ResultsPreview next weekâs market movers: jobs data, PMI reports, major earnings from Apple and AMD, and IPO buzz. Read here for more details.
MARKET WIREBenzinga • 17d ago
Eli Lilly Takes 19.9% Stake In TRex Bio With 5.48M Shares, Investing $12.3M In IPOThe Reporting Person beneficially owns an aggregate of 5,480,872 shares of Common Stock of the Issuer, consisting of (a) 2,510,411 shares of Common Stock that were issued to the Reporting Person upon conversion of
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRXB)
- ✓Walkthrough of TRXB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TRXB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.57%📐 HORIZONTAL RANGE
2026-11-03O $13.47H $14.05L $13.33C $13.64VOL 54.9K
SUP: $13.08SMA50: $14.10
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TRXB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on TRXB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TRXB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TRXB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRXB)
Health Care Rank #288 of 1015
⚔️ AGMB vs TRXB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TRXB vs. AGMB, TECX, ZURA, PROK)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, TRex Bio Inc. (TRXB) ranks #288 by composite RQD confidence (48/100, grade D) and #482 by equity capitalization ($377.1M). Within this direct 5-issuer industry benchmark cohort, TRXB leads on earnings valuation at N/A trailing P/E, while TECX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TRXB currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TRXB
ACTIVE
TRex Bio Inc. | D | 48/100 | — | — | — | -0.73% | $377.1M | Benchmark Subject |
| AGMB AgomAb Therapeutics NV | D | 45/100 | — | — | — | -10.28% | $368.9M | /agmb-vs-trxb → |
| TECX Tectonic Therapeutic Inc. | E | 30/100 | — | — | -35.0% | -4.04% | $386.7M | /tecx-vs-trxb → |
| ZURA Zura Bio Limited (Class A) | E | 29/100 | — | — | -35.0% | -2.47% | $389.2M | /zura-vs-trxb → |
| PROK ProKidney Corp. (Class A) | D- | 35/100 | — | — | -35.0% | -13.51% | $391.6M | /prok-vs-trxb → |
2. TRXB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTTRex Bio Inc. (TRXB) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $377.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. TRXB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TRXB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, TRex Bio Inc. (NASDAQ: TRXB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $13.64 (-0.73% 1D, market cap $377.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, TRXB ranks #288 in composite RQD confidence.
How does TRXB compare to AGMB and TECX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TRXB carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AGMB (AgomAb Therapeutics NV) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $368.9M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, TRXB leads on earnings multiple (N/A) while TECX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TRXB?
For TRex Bio Inc. (TRXB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #288 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TRXB trading relative to its 50-day, 200-day, and 52-week technical levels?
TRXB last traded at $13.64 (-0.73% on volume of 54,856 shares), positioning the stock -3.81% below its 50-day simple moving average ($14.18) and -1.30% below its 200-day simple moving average ($13.82). Across its 52-week range of $13.10 to $16.56, TRXB sits at the 15.6% percentile with a 14-day RSI of 49.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.93 to $15.35).
ROARABLE RATING BRIEF • RQD 48/100 (D)
✓ SEC XBRL & RQD VERIFIED
TRXB — TRex Bio Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
TRex Bio Inc. (TRXB) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $13.64 (-0.73% 1D, market capitalization $377.1M).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
— The profile identifies TRex Bio Inc. As a NASDAQ-listed Health Care issuer in Biotechnology: Biological Products (No Diagnostic Substances) with a market capitalization of $0.4B.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 48/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $13.10 – $16.56 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), TRXB carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can TRXB sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $16.56 52-week high?
- Key Question #3: How sensitive is TRXB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
TRXB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for TRex Bio Inc. (TRXB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
How to Play TRXB Stock After the TRex Bio IPO Yahoo Finance report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Fierce Biotech • 1d ago
TRex rakes in $117M IPO, while Retension reveals $45M listing Fierce Biotech report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Eli Lilly-backed TRex Bio targets up to $133M in U.S. IPO Seeking Alpha report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Barron's • 1d ago
TRex Bio Inc. Stock Grades | TRXB Barron's report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
TRex Bio, Inc. Income Statement – NASDAQ:TRXB TradingView report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
TRex Bio, Inc. (TRXB) stock price, news, quote and history Yahoo Finance UK report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
TRex Bio (TRXB) Stock Price, News & Analysis Stock Titan report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Renaissance Capital • 1d ago
TRXB IPO News - Autoimmune and inflammatory diseases biotech TRex Bio sets terms for $125 million IPO Renaissance Capital report covering TRex Bio Inc. (TRXB) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
TRXB Bull vs. Bear Conversation Board — What's Your Call at $13.64?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TRXB 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $17.60 (+29.0%)
📌 Pinned Debate Balance sheet forensics are the relative strength, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 contributing 13 of 20 points
The street is overcomplicating TRex Bio Inc. (TRXB). Balance sheet forensics are the relative strength, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5 contributing 13 of 20 points.. With an RQD score of 48/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $14.73.
SectorRotator 🐂 BULL
@MacroHawk_NYC Agree on the RQD 48/100 quality, though with 1.0 beta I'm scaling in with half-size at $13.64 and keeping dry powder in case we test $12.69.
ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH
🎯 Target: $10.91 (-20.0%)
Spot @ $13.64 Zero ROIC and zero FCF yield leave the cash engine at 12 of 20 points, with whale flow at 6 of 20 signalling weak institutional convict
I respect the product at TRex Bio Inc., but the stock at $13.64 is a different story. Zero ROIC and zero FCF yield leave the cash engine at 12 of 20 points, with whale flow at 6 of 20 signalling weak institutional conviction.. FCF yield is 0.0% and RQD sits at 48/100 (D) — why pay up here when you can wait for next quarter's numbers?